294,961 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Purchased by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 294,961 shares of the company’s stock, valued at approximately $7,132,000. Jupiter Asset Management Ltd. owned 0.14% of Hims & Hers Health as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of HIMS. Main Management ETF Advisors LLC bought a new position in shares of Hims & Hers Health in the third quarter worth about $672,000. Royce & Associates LP lifted its holdings in shares of Hims & Hers Health by 17.0% in the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock worth $6,281,000 after acquiring an additional 49,500 shares during the last quarter. Versor Investments LP bought a new position in shares of Hims & Hers Health in the third quarter worth about $634,000. Blueshift Asset Management LLC lifted its holdings in shares of Hims & Hers Health by 834.8% in the third quarter. Blueshift Asset Management LLC now owns 245,013 shares of the company’s stock worth $4,513,000 after acquiring an additional 218,804 shares during the last quarter. Finally, Means Investment CO. Inc. lifted its holdings in shares of Hims & Hers Health by 23.5% in the fourth quarter. Means Investment CO. Inc. now owns 50,040 shares of the company’s stock worth $1,210,000 after acquiring an additional 9,508 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 4,152 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now owns 157,345 shares of the company’s stock, valued at $9,549,268.05. This trade represents a 2.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Andrew Dudum sold 78,127 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $29.62, for a total transaction of $2,314,121.74. Following the sale, the chief executive officer now directly owns 109,956 shares of the company’s stock, valued at approximately $3,256,896.72. This trade represents a 41.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 969,191 shares of company stock valued at $34,005,375 in the last quarter. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $31.47 on Friday. The company has a market capitalization of $6.99 billion, a PE ratio of 71.51 and a beta of 1.37. The company has a 50 day simple moving average of $38.36 and a two-hundred day simple moving average of $27.92. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Needham & Company LLC increased their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Piper Sandler raised their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, February 25th. Leerink Partners raised their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Truist Financial raised their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a report on Wednesday, February 26th. Finally, Morgan Stanley lowered shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $42.00 to $60.00 in a report on Tuesday, February 18th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $37.23.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.